Top Sites>Pharmaceutical Executive - Leadership, Strategy & Market Access

User-agent: *
Disallow: /search
Disallow: /preview/
Disallow: /*[*]*$
Sitemap: https://www.pharmexec.com/sitemap.xml
Sitemap: https://www.pharmexec.com/sitemap-news.xml

# PharmExec

> PharmExec - Healthcare Publication

- Base URL: https://www.pharmexec.com
- Generated: 2026-04-25T05:27:26.363Z
- Content updates: multiple times daily

## Content Access for AI Agents

This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML.

**Supported content types:**
- `text/markdown` — Clean Markdown with YAML frontmatter
- `text/plain` — Plain text (same as Markdown)
- `text/html` — Default HTML response

**Example request:**
```
curl -H "Accept: text/markdown" https://www.pharmexec.com/view/article-slug
```

**YAML frontmatter schema** (returned with every Markdown response):

| Field | Type | Description |
|-------|------|-------------|
| `title` | string | Article headline |
| `description` | string | Summary/excerpt (max 300 chars) |
| `url` | string | Canonical article URL |
| `canonical_url` | string | Canonical URL if different from `url` |
| `published` | ISO 8601 | Original publication date |
| `modified` | ISO 8601 | Last modification date |
| `authors` | string[] | Author display names |
| `content_type` | string | Content category (e.g., "News", "Clinical") |
| `categories` | string[] | Taxonomy categories |
| `tags` | string[] | SEO tags |
| `image` | string | Featured image URL |
| `publisher` | string | Publication/site name |

**Discovery headers** (included on all responses):
- `Link: <https://www.pharmexec.com/llms.txt>; rel="llms"` — RFC 8288 link to this file
- `X-Llms-Txt: https://www.pharmexec.com/llms.txt` — Explicit discovery header

## Usage Policy

- Robots policy: [https://www.pharmexec.com/robots.txt](https://www.pharmexec.com/robots.txt)
- Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329)
- Rate guidance: prefer RSS and sitemap feeds over crawling individual pages
- Attribution: All content © MJH Life Sciences. Include source URLs when citing.

## Content Categories

- [Content Engagement Hubs](https://www.pharmexec.com/content-engagement-hubs)
- [Country Reports](https://www.pharmexec.com//topic/country-reports)
- [Editorial Podcasts](https://www.pharmexec.com/editorial-podcasts)
- [Editorial Videos](https://www.pharmexec.com/editorial-videos)
- [Events](https://www.pharmexec.com/events)
- [Front & Center](https://www.pharmexec.com/front-center)
- [News](https://www.pharmexec.com/news)
- [Pharma Pulse](https://www.pharmexec.com/pharma-pulse)
- [Profiles in Medicine](https://www.pharmexec.com/profiles-in-medicine)
- [Sponsored Content](https://www.pharmexec.com/sponsored-content)
- [Sponsored Podcasts](https://www.pharmexec.com/sponsored-podcasts)
- [Sponsored Videos](https://www.pharmexec.com/sponsored-videos)
- [Topic](https://www.pharmexec.com/topic)
- [Video Series](https://www.pharmexec.com/video-series)
- [Webcasts](https://www.pharmexec.com/webcasts)
- [Whitepapers](https://www.pharmexec.com/whitepapers)

## Featured Content

- [FDA Awards Priority Voucher to Compass for Psychedelic Therapy in Treatment-Resistant Depression](https://www.pharmexec.com/view/fda-priority-voucher-compass-psychedelic-treatment-resistant-depression): FDA granted Compass Pathways with a rolling review for COMP360, a proprietary formulation of synthetic psilocybin, in treatment-resistant depression.
- [Pharmaceutical Executive Daily: FDA Issues CRL to AbbVie](https://www.pharmexec.com/view/daily-fda-issues-crl-abbvie): In today’s Pharmaceutical Executive Daily, the FDA issues a complete response letter to AbbVie for a biologics license application, Regeneron moves to...
- [FDA Issues CRL to AbbVie for TrenibotulinumtoxinE’s Biologics License Application ](https://www.pharmexec.com/view/fda-issues-crl-abbvie-trenibotulinumtoxine-biologics-license-application): FDA issues Complete Response Letter to AbbVie’s trenibotulinumtoxinE, delaying a potential first-in-class aesthetic neurotoxin over manufacturing ques...
- [Regeneron Agrees to Lower Drug Costs for U.S. Patients and Provide Otarmeni for Free](https://www.pharmexec.com/view/regeneron-agrees-lower-drug-costs-us-patients-provide-otarmeni-free): Regeneron announces agreement with the U.S. Government to set drug prices similarly to foreign prices, along with providing a new gene therapy free to...
- [The Long Wait for Rare Disease Treatment Approval: Q&A with Dr. Patricia E. Greenstein](https://www.pharmexec.com/view/long-wait-rare-disease-treatment-approval-patricia-greenstein): Traditional randomized trials are often impractical for treatments in the rare and ultra rare disease space.
- [Lessons Learned in the Current Biotech Funding Environment](https://www.pharmexec.com/view/lessons-learned-current-biotech-funding-environment): Maher Masoud, CEO of MaxCyte, explains how the current environment is impacting the entrepreneurial spirit in the pharmaceutical industry.
- [The Ron Lanton Report: Where Innovations Happen](https://www.pharmexec.com/view/ron-lanton-report-where-innovations-happen): In this episode, Ron Lanton examines how geography is becoming a central strategic variable in healthcare, as policy, trade dynamics, and infrastructu...
- [FDA Approves Otarmeni Gene Therapy for OTOF-Related Hearing Loss](https://www.pharmexec.com/view/fda-otarmeni-gene-therapy-otof-related-hearing-loss): Early clinical data from the CHORD trial supported accelerated approval of the first gene therapy targeting OTOF-related hearing loss under the FDA Co...
- [Pharmaceutical Executive Daily: FDA Expands Approvals for Tzield and Dupixent](https://www.pharmexec.com/view/daily-fda-expands-approvals-tzield-and-dupixent): In today’s Pharmaceutical Executive Daily, the FDA expands the use of Tzield to young children to delay the onset of stage 3 type 1 diabetes, Dupixent...
- [FDA Approves Tzield to Delay Onset of Stage 3 Type 1 Diabetes in Young Children](https://www.pharmexec.com/view/fda-approves-tzield-delay-onset-stage-3-type-1-diabetes-young-children): FDA expands its approval of Tzield to children as young as one with stage 2 type 1 diabetes, extending the first disease-modifying therapy into an ear...

## Feeds and Indexes

- [RSS Feed](https://www.pharmexec.com/rss.xml): Latest articles in XML syndication format
- [Sitemap](https://www.pharmexec.com/sitemap.xml): Complete URL index for all published pages
- [News Sitemap](https://www.pharmexec.com/sitemap-news.xml): Recent articles optimized for news indexing
- [Authors Directory](https://www.pharmexec.com/authors): Browse all contributors and their published work